Latest news
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - TradingViewTradingView · Sat, 08 Aug 2026 00:31:44 GMTReplimune wins on third try as FDA clears Tudriqev for melanoma - FirstWord PHARMAFirstWord PHARMA · Fri, 07 Aug 2026 00:57:10 GMTFDA Finally OKs Twice-Rejected Melanoma Drug - MedPage TodayMedPage Today · Thu, 06 Aug 2026 21:40:02 GMTReplimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections - Endpoints NewsEndpoints News · Thu, 06 Aug 2026 20:03:00 GMTBristol-Myers Squibb suffers another EPO Opdivo patent loss - IAM PatentIAM Patent · Thu, 06 Aug 2026 13:32:21 GMTOpdivo gains Korean approval for perioperative treatment of resectable NSCLC - koreabiomed.comkoreabiomed.com · Thu, 06 Aug 2026 06:08:05 GMTBristol Myers Squibb: 2Q Growth Portfolio Revenue Increase Primarily Driven by Opdivo Qvantig, Reblozyl, Camzyos, Opdualag and Breyanzi >BMY - MoomooMoomoo · Thu, 30 Jul 2026 10:59:00 GMTDid Opdivo Combo Filing and AI-Driven R&D Expansion Just Shift Bristol-Myers Squibb's (BMY) Investment Narrative? - simplywall.stsimplywall.st · Thu, 30 Jul 2026 05:21:46 GMT